N/A N=80 Electrical Stimulation for Recovery of Hand Function in Chronic Stroke Survivors
Stroke · Hemiparesis · Hemiplegia
Primary: Change in Box and Block Test Score at 6 Mo Post-Treatment — 4.6; 1.8 blocks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Monoclonal Antibody-based Multipurpose Microbicides
HIV · Sexually Transmitted Infections (STI)
Primary: Frequency of Use — 1.14; 1.31; 0.00; 0.00 units on a scale
N/A N=117 Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR Images
Clinical Indication for Brain MRI
Primary: Mean Diagnostic Image Quality Difference Between Conventional Versus Synthetic MR Utilizing a 5 Point Likert Scale — -0.335 units on a 5-point scale — p=<0.001
Phase 2 N=70 A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour]) — -6.58; -8.25; -1.40…
Phase 3 N=1,249 The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Colorectal Cancer
Primary: To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the…
N/A N=8 A Feasibility Device Study to Prevent Female Urinary Stress Incontinence
Stress Incontinence, Female
Primary: Pad Weight Difference — 0.0; 0.0; 0.0; 0.3 grams — p=0.0469
Phase 2 N=14 MC-5A for Chemotherapy Induced Peripheral Neuropathy
Neuropathy, Paraneoplastic
Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters
Phase 2 N=48 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Phase 3 N=83 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Dyskinesia · Levodopa Induced Dyskinesia · Parkinson's Disease
Primary: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8 — -6.7; -12.3; -17.9; -16.7 units on a scale — p=0.0051
Phase 2 N=23 Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS
Mild, Allergic Asthma
Primary: Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Reference Endotoxin (CCRE) Challenge as Affected by Gamma Tocopherol — 11.7…
N/A N=45 Examining the Efficacy of Mattress Technology in Improving the Sleep Quality of Children With ASD
Autism Spectrum Disorders
Primary: Compare Percentage of Participants Who Drop Out of Study as a Measure of Toleration of Mattress Technology — 1; 1 Participants — p=<.001
Phase 1 N=13 Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Breast Neoplasms · Stomach Neoplasms
Primary: MTD of Afatinib in Combination With Trastuzumab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib). — 20 mg
N/A N=122 ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
Diabetes Mellitus, Type 1
Primary: Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24 — 14.3 score on a scale
N/A N=121 Trauma Survivors Outcomes and Support Study IV
Posttraumatic Stress Disorder · Depression · Suicide
Primary: Change in Post Traumatic Stress Disorder (PTSD) Symptoms Over the Course of the Six Months After Injury — 47.0; 47.0; 43.9; 43.6 units on a scale — p=0.05
Phase 4 N=6 Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
Parkinson's Disease · Deep Brain Stimulation Surgery
Primary: Change in Average Population Spiking Activity — 42.8 Percent change